Alnylam Pharmaceuticals, Inc.
ALNY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $30 | $24 | $29 | $20 |
| - Cash | $1 | $1 | $1 | $1 |
| + Debt | $1 | $1 | $1 | $1 |
| Enterprise Value | $30 | $24 | $29 | $20 |
| Revenue | $2 | $2 | $1 | $1 |
| % Growth | 23% | 76.2% | 22.9% | – |
| Gross Profit | $2 | $2 | $1 | $1 |
| % Margin | 85.6% | 83% | 83.7% | 83.4% |
| EBITDA | -$0 | -$0 | -$1 | -$1 |
| % Margin | -8% | -14.1% | -89.3% | -78.4% |
| Net Income | -$0 | -$0 | -$1 | -$1 |
| % Margin | -12.4% | -24.1% | -109% | -101% |
| EPS Diluted | -2.18 | -3.52 | -9.3 | -7.2 |
| % Growth | 38.1% | 62.2% | -29.2% | – |
| Operating Cash Flow | -$0 | $0 | -$1 | -$1 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | $0 | -$1 | -$1 |